

# Judith E Karp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9457300/publications.pdf>

Version: 2024-02-01

19  
papers

1,056  
citations

858243

12  
h-index

993246

17  
g-index

19  
all docs

19  
docs citations

19  
times ranked

2128  
citing authors

#	ARTICLE	IF	CITATIONS
1	The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?. <i>EJHaem</i> , 2022, 3, 301-313.	0.4	9
2	CDK2-Mediated Upregulation of TNF $\alpha$ as a Mechanism of Selective Cytotoxicity in Acute Leukemia. <i>Cancer Research</i> , 2021, 81, 2666-2678.	0.4	5
3	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory) Tj ETQq1 1 0.78&4314 rgBT /Over		
4	Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7&#x2013;3) in newly diagnosed high-risk acute myeloid leukemia (AML). <i>Leukemia Research</i> , 2018, 72, 92-95.	0.4	30
5	Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. <i>Stem Cells Translational Medicine</i> , 2017, 6, 840-850.	1.6	5
6	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	3.2	56
7	4EBP1/c-MYC/PUMA and NF- $\kappa$ B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. <i>Blood</i> , 2016, 127, 2711-2722.	0.6	49
8	Cancer susceptibility genes and their potential implication regarding systemic therapy for early&#x2013;stage breast cancer. <i>Cancer</i> , 2016, 122, 178-180.	2.0	0
9	Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1172-1179.	1.7	93
10	Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1312-1318.	0.4	94
11	Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience. <i>Journal of Clinical Oncology</i> , 2015, 33, 340-348.	0.8	94
12	New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine. <i>Clinical Cancer Research</i> , 2014, 20, 6233-6241.	3.2	17
13	Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. <i>Clinical Cancer Research</i> , 2012, 18, 6723-6731.	3.2	100
14	Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells <i>In Vitro</i>. <i>Clinical Cancer Research</i> , 2012, 18, 5364-5373.	3.2	53
15	Phase 1 dose&#x2013;escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. <i>British Journal of Haematology</i> , 2012, 158, 198-207.	1.2	7
16	Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. <i>Blood</i> , 2007, 109, 2781-2790.	0.6	279
17	A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. <i>Blood</i> , 2007, 110, 1762-1769.	0.6	84
18	Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. <i>Blood</i> , 2006, 107, 2501-2506.	0.6	76

#	ARTICLE	IF	CITATIONS
19	Farnesyl transferase inhibition in hematologic malignancies. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3 Suppl 1, S37-40.	2.3	0